Jul 12, 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
Jul 09, 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington's Disease
Jun 27, 2019
A Boost of Klotho Protein Level Has Therapeutic Potential in Amyotrophic Lateral Sclerosis (ALS), Also Known as Lou Gehrig's Disease
Jun 27, 2019
ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Jun 19, 2019
ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
Jun 12, 2019
Nitrome Biosciences Awarded a Michael J. Fox Foundation Target Advancement Grant to Discover a New Drug Target for Parkinson's Disease
Jun 05, 2019
ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
May 23, 2019
APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research
May 20, 2019
A New Approach to Treating Alzheimer's Disease Receives Major NIA Backing
May 14, 2019
ProMIS Neurosciences Announces First Quarter 2019 Results
May 13, 2019
4D Announces Participation in Neuro4D Conference, Frankfurt, Germany
May 05, 2019
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
May 01, 2019
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
Apr 23, 2019
ProMIS Neurosciences to Participate in the Think Equity Investor Conference
Apr 15, 2019
EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications
Apr 05, 2019
Dystrogen Therapeutics Announces That Gene Therapy Successfully Cuts Off Production of Neuron-Destroying Protein in Huntington's Disease
Mar 26, 2019
CERESPIR INCORPORATED Assembles World Class Clinical Advisory Board Chaired by Professor Robert A. Hauser to Support CERESPIR's Parkinson's Disease Development Program for Itanapraced
Mar 21, 2019
Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease
Mar 21, 2019
Blackfynn announces an expanded partnership with The Michael J. Fox Foundation, extends its neurodegenerative disease data ecosystem and Dr. Karl Kieburtz joins as Head of Clinical Development
Mar 21, 2019
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease